All Q2 FY27 results →
GC

GOCL Corpn.

Q2 FY27Chemicals & Petrochemicals

GOCL Corpn. Q2 FY27 results statement: Revenue & Margins

Q2 FY27 results statement: what the company reported on revenue, margins and projects.

Price₹369
Market cap₹1.8K Cr
P/E6.8
Updated20 Oct 2026
Read3 min read

Based on GOCL Corpn.'s Q2 FY27 results statement. The company has not published an earnings-call transcript for this quarter, so figures here are what the results statement reports, not management guidance.

The short version

Revenue from operations (Standalone) for quarter ended Sept 30, 2026: Rs. Quarterly EBITDA: Rs.

From GOCL Corpn.'s Q2 FY27 earnings-call transcript · updated 20 Oct 2026.

Revenue & Sales Performance

  • Revenue from operations (Standalone) for quarter ended Sept 30, 2026: Rs. 41,063 lakhs
  • Revenue from operations for quarter ended Sept 30, 2025: Rs. 22,202 lakhs
  • Year-on-year (YoY) increase in revenue from operations: Approximately 85% increase (41,063 vs. 22,202 lakhs)
  • Total income for the quarter ended Sept 30, 2026: Rs. 60,322.4 lakhs (Standalone) vs Rs. 45,312 lakhs for same quarter previous year
  • Discontinued operations income for the quarter ended Sept 30, 2026: Rs. 267.44 lakhs compared to Rs. 8,727.45 lakhs in Sept 30, 2025 (significant decline due to discontinuation)

2 more points from GOCL Corpn.'s call on revenue

Pro opens every point from 15K+ earnings calls

Profitability & Margins

See what GOCL Corpn. said on profitability & margins — free account, 30 seconds.

Capital Expenditure Plans

The presentation does not explicitly describe any capital expenditure (capex), capacity expansion, or new plant/project details such as amounts, status, or timelines. The key points relevant to asset transactions include: - Sale Agreement for property "Ecopolis" at Yelahanka, Bengaluru, with consideration of approximately Rs. 81,500 lakhs. Property reclassified as "Non-current Assets Held for Sale"; transaction pending completion, no sale executed yet. - No new plant or project capex or capacity expansion mentioned. - Acquisition or expansion plans are not detailed.

2 more points from GOCL Corpn.'s call on capex

Pro opens every point from 15K+ earnings calls

Top-ranked in Chemicals & Petrochemicals

Ranked on what management guided this quarter

Guidance-ranked
1Shiv Texchem
Rev 1Mar 2
Rev 1Mar 3
3
Rev 1Mar 3
4
Rev 1Mar 3
5
Rev 2Mar 1
Sign up free to see 3 moreTakes 30 seconds · no cardSign up

Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.

Fundraising & Capital Structure

See what GOCL Corpn. said on fundraising & capital structure — free account, 30 seconds.

Order Book & Pipeline

  • The presentation does not explicitly report any figures or details related to order book, order inflow, or pending orders.
  • It primarily focuses on unaudited standalone and consolidated financial results, notes on corporate guarantees, merger scheme, sale of property, and related audit observations.
  • No specific metrics or discussions about current order backlog, new orders received, or orders pending execution are mentioned in the text.

GOCL Corpn. — Quarterly revenue & net profit

Revenue Net profit
Jun 2025Q1 FY26
Sep 2025Q2 FY26
Dec 2025Q3 FY26
Mar 2026Q4 FY26
Jun 2026Q1 FY27
Sep 2026Q2 FY27

Reported quarterly figures (₹ Cr). Latest (Q2 FY27): revenue ₹4 Cr, net profit ₹40 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.

Full financials →

Others in Chemicals & Petrochemicals this season

  • AksharChem (I) (Q2 FY27)

    Year-on-year revenue growth for the quarter is approximately 79.7% [(16,048.24 . Key results statement takeaways from AksharChem (I)'s Q2 FY27 results statement

  • Bhansali Engineering Polymers Ltd (Q2 FY27)

    Revenue from operations (net) for the quarter ended 30/09/2026 is ₹40,336.95 lakhs, compared to ₹32,509.76 lakhs for the quarter ended 30/09/2025, reflecting a…

  • Tatva Chintan (Q2 FY27)

    Q2 FY27 revenue from operations: ₹2,173 Mn, up 76% YoY from ₹1,235 Mn in Q2 FY26 (Page 11). Key investor presentation takeaways from Tatva Chintan's Q2 FY27 inv

  • Rossari Biotech (Q2 FY27)

    4,195.12 million, an increase of approximately 18%. Key investor presentation takeaways from Rossari Biotech's Q2 FY27 investor presentation — and how it ranks

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →

Arthneeti Pro · Annual

GOCL Corpn. and 15K+ more earnings calls,
for less than your morning chai

a day

Every earnings call, ranking and concall Q&A across all four results seasons.

Secure Razorpay payment · instant access

Frequently Asked Questions

What were GOCL Corpn. Q2 FY27 results?

Revenue from operations (Standalone) for quarter ended Sept 30, 2026: Rs. Quarterly EBITDA: Rs.

What is GOCL Corpn. share price analysis?

GOCL Corpn. currently shows a neutral. The stock trades at a P/E of 6.8 with a market cap of ₹1,828 Cr. Investors should review the full earnings analysis for detailed insights.

Is GOCL Corpn. planning capital expenditure?

The presentation does not explicitly describe any capital expenditure (capex), capacity expansion, or new plant/project details such as amounts, status, or timelines.

Keep GOCL Corpn. on your radar — track it to get its next earnings analysis in your feed.

This analysis is AI-generated based on publicly available earnings data and the company's results statement. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.